Harbor Therapeutics Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (1992)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
1999
NCT00002422
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Hollis-Eden

Active Ingredients

Drugs in Phase 2 Trials (2)

he3235 (1 trial)

he3286 (5 trials)

Drugs in Phase 1 Trials (1)

he2000 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

HIV Infections (Phase 1)

Insulin Resistance (Phase 1)

Prostatic Neoplasms (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 3